Exelixis (EXEL)

Exelixis Stock Analysis & Ratings

EXEL Stock Chart & Stats

Day’s Range$19.87 - $20.195
52-Week Range$15.50 - $25.77
Previous Close$19.8
Average Volume (3M)2.21M
Market Cap$6.44B
P/E Ratio28.1
Next EarningsAug 03, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score5
EPS (TTM)0.72



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Exelixis’s price range in the past 12 months?
Exelixis lowest stock price was $15.50 and its highest was $25.77 in the past 12 months.
    What is Exelixis’s market cap?
    Exelixis’s market cap is $6.44B.
      What is Exelixis’s price target?
      The average price target for Exelixis is $31.50. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $42.00 ,the lowest forecast is $23.00. The average price target represents 56.87% Increase from the current price of $20.08.
        What do analysts say about Exelixis?
        Exelixis’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.
          When is Exelixis’s upcoming earnings report date?
          Exelixis’s upcoming earnings report date is Aug 03, 2022 which is in 79 days.
            How were Exelixis’s earnings last quarter?
            Exelixis released its earnings results on May 10, 2022. The company reported $0.21 earnings per share for the quarter, beating the consensus estimate of $0.143 by $0.067.
              Is Exelixis overvalued?
              According to Wall Street analysts Exelixis’s price is currently Undervalued.
                Does Exelixis pay dividends?
                Exelixis does not currently pay dividends.
                What is Exelixis’s EPS estimate?
                Exelixis’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Exelixis have?
                Exelixis has 320,740,000 shares outstanding.
                  What happened to Exelixis’s price movement after its last earnings report?
                  Exelixis reported an EPS of $0.21 in its last earnings report, beating expectations of $0.143. Following the earnings report the stock price went up 0.354%.
                    Which hedge fund is a major shareholder of Exelixis?
                    Among the largest hedge funds holding Exelixis’s share is Hussman Strategic Advisors Inc. It holds Exelixis’s shares valued at 589K.


                      Exelixis Stock Analysis

                      The Exelixis stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description


                      Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of Cometriq, Cabometyx, and Cotellic. The company was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994 and is headquartered in Alameda, CA.

                      Similar Stocks
                      Price & Change
                      Merck & Company
                      Roche Holding
                      Bristol Myers
                      Sanofi-Aventis Sa

                      Popular Stocks

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis